Sponsor
Astellas Pharma Global Development, Inc.
Clinical research sponsor
Clinical trials
49 shownA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsNCT07730021 · lead sponsor · 2026-09-02
RECRUITINGA Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamageNCT07770685 · lead sponsor · 2026-08-14
RECRUITINGA Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsNCT07488676 · lead sponsor · 2026-05-04
RECRUITINGA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052 · lead sponsor · 2026-04-28
RECRUITINGA Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsNCT07287995 · lead sponsor · 2026-02-05
RECRUITINGA Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267 · lead sponsor · 2026-01-20
RECRUITINGA Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)NCT07140016 · lead sponsor · 2025-09-22
RECRUITINGA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · lead sponsor · 2025-08-19
RECRUITINGSafety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerNCT05997615 · lead sponsor · 2023-08-10
RECRUITINGA Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerNCT04729114 · lead sponsor · 2021-06-14
RECRUITINGA Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerNCT07783282 · lead sponsor · 2026-08-31
NOT_YET_RECRUITINGA Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsNCT06681870 · lead sponsor · 2024-12-31
WITHDRAWNExperiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer PatientsNCT06500741 · lead sponsor · 2024-11-22
COMPLETEDA Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's SyndromeNCT06544642 · lead sponsor · 2024-08-21
TERMINATEDA Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967 · lead sponsor · 2024-07-31
ACTIVE_NOT_RECRUITINGXNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.NCT06792435 · lead sponsor · 2023-07-27
ACTIVE_NOT_RECRUITINGSurvey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) StudyNCT05381311 · lead sponsor · 2021-09-03
COMPLETEDA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)NCT04225117 · lead sponsor · 2020-03-10
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerNCT04094519 · lead sponsor · 2020-01-27
COMPLETEDA Study of ASP1951 in Subjects With Advanced Solid TumorsNCT03799003 · lead sponsor · 2019-01-14
TERMINATEDA Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · lead sponsor · 2018-07-13
COMPLETEDA Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsNCT03565445 · lead sponsor · 2018-07-02
COMPLETEDA Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With SchizophreniaNCT03356639 · lead sponsor · 2018-01-22
COMPLETEDA Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsNCT03082300 · lead sponsor · 2017-03-24
TERMINATEDA Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 StudyNCT03042013 · lead sponsor · 2017-02-28
WITHDRAWNA Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · lead sponsor · 2016-12-22
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid ArthritisNCT02867306 · lead sponsor · 2016-07-25
COMPLETEDA Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary DiseaseNCT02662582 · lead sponsor · 2016-06-30
COMPLETEDA Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceNCT02799745 · lead sponsor · 2016-06-09
COMPLETEDA Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With SchizophreniaNCT02720263 · lead sponsor · 2016-03-28
COMPLETEDA Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT02677896 · lead sponsor · 2016-03-09
COMPLETEDA Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on MethotrexateNCT02698657 · lead sponsor · 2016-02-23
COMPLETEDA Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsNCT02588261 · lead sponsor · 2016-02-11
TERMINATEDA Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentNCT02441517 · lead sponsor · 2015-10-28
TERMINATEDA Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)NCT02495233 · lead sponsor · 2015-09-08
TERMINATEDObservational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)NCT02380274 · lead sponsor · 2015-03-27
COMPLETEDA Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerNCT02091960 · lead sponsor · 2014-09-05
COMPLETEDA Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsNCT02113813 · lead sponsor · 2014-04-09
COMPLETEDA Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CancerNCT02066961 · lead sponsor · 2013-12-31
COMPLETEDA Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideNCT01977651 · lead sponsor · 2013-09-25
COMPLETEDA Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyNCT01711814 · lead sponsor · 2012-09-26
COMPLETEDA Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01663415 · lead sponsor · 2012-08-01
WITHDRAWNA Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsNCT01650194 · lead sponsor · 2012-07-09
COMPLETEDA Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisNCT01565655 · lead sponsor · 2012-06-19
COMPLETEDA Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on MethotrexateNCT02052375 · lead sponsor · 2012-06-01
COMPLETEDA Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on MethotrexateNCT02171143 · lead sponsor · 2012-04-01
COMPLETEDA Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) InjectionsNCT02150070 · lead sponsor · 2011-08-01
COMPLETEDProvide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyNCT01606982 · lead sponsor
APPROVED_FOR_MARKETINGStereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)NCT01573702 · collaborator · 2012-12-11
COMPLETEDSponsor roles
lead sponsor48
collaborator1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.